Kyung Dong Pharmaceutical Co., Ltd.

Equities

A011040

KR7011040003

Pharmaceuticals

End-of-day quote Korea S.E. 06:00:00 2024-04-25 pm EDT 5-day change 1st Jan Change
6,380 KRW +0.16% Intraday chart for Kyung Dong Pharmaceutical Co., Ltd. +1.92% -3.48%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Kyung Dong Pharmaceutical Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Kyung Dong Pharmaceutical Co., Ltd. announces an Equity Buyback for 200,000 shares. CI
Kyung Dong Pharmaceutical Co., Ltd. authorizes a Buyback Plan. CI
Kyung Dong Pharmaceutical Co., Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
Kyung Dong Pharmaceutical Co., Ltd.(KOSDAQ:A011040) dropped from S&P Global BMI Index CI
Kyung Dong Pharmaceutical Co., Ltd. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023 CI
Kyung Dong Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023 CI
Kyung Dong Pharmaceutical Co., Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022 CI
Tranche Update on Kyung Dong Pharmaceutical Co., Ltd.'s Equity Buyback Plan announced on September 16, 2022. CI
Kyung Dong Pharmaceutical Co., Ltd.'s Equity Buyback announced on September 16, 202, has closed with 100,000 shares, representing 0.37% for KRW 749.64 million. CI
Kyung Dong Pharmaceutical Co., Ltd. announces an Equity Buyback for 100,000 shares. CI
Kyung Dong Pharmaceutical Co., Ltd. authorizes a Buyback Plan. CI
Kyung Dong Pharmaceutical Co., Ltd. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022 CI
Kyung Dong Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2022 CI
Eight South Korean Firms to Donate $2.4 Million Worth of Medicine to Ukraine MT
Kyung Dong Pharmaceutical Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2021 CI
Kyung Dong Pharmaceutical Co., Ltd.'s Equity Buyback announced on August 17, 2021, has expired. CI
Kyung Dong Pharmaceutical Co., Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2021 CI
Kyung Dong Pharmaceutical Co., Ltd. announces an Equity Buyback for 300,000 shares. CI
Kyung Dong Pharmaceutical Co., Ltd. authorizes a Buyback Plan. CI
Tranche Update on Kyung Dong Pharmaceutical Co., Ltd.'s Equity Buyback Plan announced on May 10, 2021. CI
Kyung Dong Pharmaceutical Co., Ltd.'s Equity Buyback announced on May 10, 2021, has closed with 250,000 shares, representing 0.9% for KRW 2,671.22 million. CI
Kyung Dong Pharmaceutical Co., Ltd. announces an Equity Buyback for 250,000 shares. CI
Kyung Dong Pharmaceutical Co., Ltd. authorizes a Buyback Plan. CI
Kyung Dong Pharmaceutical Co., Ltd.(KOSDAQ:A011040) added to S&P Global BMI Index CI
Chart Kyung Dong Pharmaceutical Co., Ltd.
More charts
KYUNG DONG PHARMACEUTICAL CO.,LTD. is a Korea-based company engaged in the manufacture and marketing of pharmaceutical products. The Company’s products include liver therapies, gastrointestinal drugs, antimigraine drugs, antiviral, anti-obesity medications, antibacterial drugs, antidiabetic drugs, antifungal, allergy medications, antispasmodics, antihistamines, vitamins, as well as drugs for osteoporosis, cardiovascular, muscle relaxant, neuropathic and other diseases. It also provides various over-the-counter (OTC) drugs, such as anti-inflammatory medicines, antiviral drugs, antihistamine drugs, gastrointestinal drugs and others. In addition, the Company engages in the leasing of real estate, and distribution of snowboards and health functional food.
More about the company
  1. Stock Market
  2. Equities
  3. A011040 Stock
  4. News Kyung Dong Pharmaceutical Co., Ltd.
  5. Eight South Korean Firms to Donate $2.4 Million Worth of Medicine to Ukraine